Pharmaceutical Manufacturers NAICS 3254

Mar 3, 2026 - Countries may Choose to Keep Existing Tariff Deals

• President Trump said in his State of the Union Address that almost all countries and corporations want to keep trade deals already completed in order to avoid the higher tariffs enacted via an executive order issued shortly after the US Supreme Court ruled in late February 2026 that President Trump exceeded his authority when imposing tariffs using a law reserved for a national emergency. Pharmaceutical manufacturers are likely to benefit if the cost of goods imported from countries that were hit with tariffs decreases. The executive order implements a new tariff under Section 122 of the 1974 Trade Act. Section 122 allows the president to institute a "temporary import surcharge" of up to 15% if he finds there are "large and serious United States balance of-payments deficits" or to "prevent an imminent and significant depreciation of the [US] dollar in foreign exchange markets." The tariffs can last for up to 150 days, after which Congress may have to take action to extend them, according to NBC News, and the law is also not clear on whether the administration could restart the tariffs immediately after the 150 days with another executive order.
• Only 17% of pharmaceutical industry organizations surveyed by data security firm Kiteworks have implemented automated controls to prevent sensitive data from leaking through AI tools. The remaining 83% depend on human-centered approaches: Forty percent rely on employee training sessions and periodic audits, essentially hoping staff will remember and follow the rules when working under pressure. Another 20% send warning emails about AI usage but never verify compliance. Ten percent have only issued guidelines, while 13% have no policies whatsoever. These organizations — including many contract development and manufacturing organizations — operate without basic technical safeguards while their employees paste molecular structures, clinical trial results, and patient records into ChatGPT, Claude, Perplexity, and other AI platforms, according to Kiteworks.

• President Trump said during a meeting with pharmaceutical and technology industry executives that companies which move their operations to plants in the US would face no tariffs, according to The Guardian. He also suggested that companies would have the time needed to repatriate some manufacturing with new or expanded operations in the US before they would face a “tariff wall”. President Trump paused his “reciprocal” tariffs for 90 days after they prompted a sell-off of US government bonds in April but he has repeatedly threatened to carry through with sectoral tariffs on the pharmaceutical industry.
• Pharmaceutical manufacturing industry employment and wages for nonsupervisory employees increased slightly during the first eight months of 2025, according to the US Bureau of Labor Statistics (BLS). Pharmaceutical manufacturers raised their prices slightly during the first nine months of 2025, according to the BLS.